IP Library › Granted Patent US 10,993,907
Granted Patent B2
US 10,993,907 · App. 16/089,194 · Granted May 4, 2021

Glucono delta-lactone for treatment of vaginal fungal infections

Inventors: Ulf Ellervik (Loddekopinge, SE); Olov Sterner (Malmo, SE); Helena Strevens (Lund, SE); Sophie Manner (Helsingborg, SE)
Assignee: Gedea Biotech AB
A61K9/0036A61K9/0034A61K9/02A61K9/20A61K31/351A61K31/366A61K31/4164A61K31/4174A61K31/4196A61K31/496A61K31/513A61K31/7004A61P31/10F27B3/12F27B14/00F27B14/061F27B14/10F27D1/1626H05B6/24F27B2014/066F27B2014/0837
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,993,907
App. No.
16/089,194
Granted
May 4, 2021
Kind
B2
Abstract

The present invention relates to a pharmaceutical formulation for vaginal administration, wherein the formulation comprises a pharmaceutical acceptable excipient and glucono δ-lactone, wherein the glucono δ-lactone is present in an amount of 5 to 99 wt % of the formulation. The invention also relates to a pharmaceutical formulation according to the invention for use in the prevention or treatment of a urogenital fungal infection. Furthermore, the invention relates to glucono δ-lactone (formula (III)), for use in the in the prevention or treatment of a fungal infection.

Claims (12)

1. A method for treatment of a fungal infection consisting of administration of a pharmaceutical formulation consisting of Glucono δ-lactone (formula (III)),

and one or more pharmaceutically acceptable excipients, to a subject in need thereof.

2. The method according to claim 1 , wherein the fungal infection is a urogenital fungal infection or a vulvovaginal fungal infection.

3. The method according to claim 2 , wherein the urogenital fungal infection or vulvovaginal fungal infection is vulvovaginal candidosis.

4. The method according to claim 3 , wherein the vulvovaginal candidosis is caused by Candida albicans, Candida glabrata, Candida krusei and/or Candida tropicalis.

5. The method according to claim 1 , wherein the glucono δ-lactone is present in an amount of 10 to 70 wt % of the formulation.

6. The method according to claim 1 , wherein the pharmaceutical formulation comprises no more than 10 wt % water.

7. The method according to claim 1 , wherein the pharmaceutically acceptable excipient is a carrier, a filler, and/or a buffering or pH-adjusting agent, or combination thereof.

8. The method according to claim 1 , wherein the pharmaceutical formulation is formulated to release a compound according to formula (III) over an extended period of time or 4 hours or more after administration.

9. The method according to claim 1 , wherein the pharmaceutical formulation is formulated as a tampon, vagitorium, vaginal aerosol, vaginal cup, vaginal gel, vaginal insert, vaginal patch, vaginal ring, vaginal sponge, vaginal suppository, vaginal cream, vaginal emulsion, vaginal foam, vaginal lotion, vaginal ointment, vaginal powder, vaginal shampoo, vaginal solution, vaginal spray, vaginal suspension, vaginal tablet, vaginal rod, vaginal disc, vaginal device, and any combination thereof, or wherein the pharmaceutical formulation is present on a sanitary article.

10. The method according to claim 9 , wherein the pharmaceutical formulation is formulated as a vagitorium, vaginal insert, vaginal ring, vaginal suppository, vaginal tablet, vaginal rod, or vaginal disc.

11. The method according to claim 9 wherein the sanitary article is a tampon, a sanitary napkin, an incontinence pad or diaper, or a panty liner.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2018
From: ELLERVIK, ULF; STERNER, OLOV; STREVENS, HELENA; MANNER, SOPHIE
To: GEDEA BIOTECH AB
Reel/Frame 047008/0085 →
Priority Claims (1)
SE 1650467-2 · Apr 6, 2016 · national
Continuity (1)
Related Publication 20190110983A1 · Apr 18, 2019
Cited By (1)
US 12,226,396